The present invention is directed to a compound having the general structure of formula (1):
useful for the treatment, prevention or amelioration of a CXCR1 or CXCR2 chemokine-mediated disease.
本发明涉及具有通式(1)的化合物:用于治疗、预防或改善CXCR1或CXCR2趋化因子介导的疾病。
CXCR1 and CXCR2 chemokine antagonists
申请人:Merck Sharp & Dohme Corp.
公开号:EP1745032B1
公开(公告)日:2013-07-31
5,6-DI-SUBSTITUTED OXADIAZOLOPYRAZINES AND THIADIAZOLOPYRAZINES AS CXC-CHEMOKINE RECEPTOR LIGANDS
申请人:Schering Corporation
公开号:EP1907399B1
公开(公告)日:2010-10-27
US7326729B2
申请人:——
公开号:US7326729B2
公开(公告)日:2008-02-05
[EN] CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS<br/>[FR] ANTAGONISTES DE CHIMIOKINES CXCR1 ET CXCR2